Loading…
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-193M | $-244M | $-145M | -151.8% | - | - |
| 2024 | $0M | $-255M | $-267M | $-257M | -106.5% | - | - |
| 2023 | $0M | $-269M | $-283M | $-274M | -98.5% | - | - |
| 2022 | $0M | $-257M | $-269M | $-311M | -54.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 272.56 | 286.13 | 270.83 | 205.71 |
| Operating Income | -272.56 | -286.13 | -270.83 | -205.71 |
| EBITDA | -256.94 | -268.58 | -255.33 | -192.96 |
| EBIT | -272.56 | -286.13 | -270.83 | -205.71 |
| Pretax Income | -269.48 | -283.25 | -266.76 | -244.17 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -269.48 | -283.25 | -266.76 | -244.17 |
| Net Income Common Stockholders | -269.48 | -283.25 | -266.76 | -244.17 |
| Total Expenses | 272.56 | 286.13 | 270.83 | 205.71 |
| Interest Income | 3.76 | 9.94 | 10.47 | 3.85 |
| Research And Development | 201 | 212.83 | 206.79 | 161.41 |
| Selling General And Administration | 71.56 | 73.30 | 64.04 | 44.30 |
| Normalized EBITDA | -256.94 | -261.57 | -253.44 | -148.35 |
| Normalized Income | -269.48 | -276.24 | -264.87 | -199.56 |
| Basic EPS | -1.43 | -1.46 | -1.16 | 0 |
| Diluted EPS | -1.43 | -1.46 | -1.16 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | -7.01 | -1.89 | -44.61 |
| Total Unusual Items Excluding Goodwill | 0 | -7.01 | -1.89 | -44.61 |
| Net Income From Continuing Operation Net Minority Interest | -269.48 | -283.25 | -266.76 | -244.17 |
| Reconciled Depreciation | 15.62 | 17.54 | 15.50 | 12.75 |
| Net Interest Income | 3.76 | 9.94 | 10.47 | 3.85 |
| Net Income From Continuing And Discontinued Operation | -269.48 | -283.25 | -266.76 | -244.17 |
| Total Operating Income As Reported | -272.56 | -293.14 | -272.72 | -250.32 |
| Diluted Average Shares | 188.34 | 194.54 | 230.89 | 0 |
| Basic Average Shares | 188.34 | 194.54 | 230.89 | 0 |
| Diluted NI Availto Com Stockholders | -269.48 | -283.25 | -266.76 | -244.17 |
| Net Income Including Noncontrolling Interests | -269.48 | -283.25 | -266.76 | -244.17 |
| Net Income Continuous Operations | -269.48 | -283.25 | -266.76 | -244.17 |
| Other Income Expense | -0.67 | -7.07 | -6.40 | -42.31 |
| Other Non Operating Income Expenses | -0.67 | -0.05 | -4.51 | 2.31 |
| Special Income Charges | 0 | -7.01 | -1.89 | -44.61 |
| Impairment Of Capital Assets | 0 | 7.01 | 1.89 | 44.61 |
| Net Non Operating Interest Income Expense | 3.76 | 9.94 | 10.47 | 3.85 |
| Interest Income Non Operating | 3.76 | 9.94 | 10.47 | 3.85 |
| General And Administrative Expense | 71.56 | 73.30 | 64.04 | 44.30 |
| Other Gand A | 71.56 | 73.30 | 64.04 | 44.30 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sana Biotechnology, Inc.this co. | SANA | $877M | - | 5.39 | -151.8% | -4.57 |
| Lumexa Imaging Holdings, Inc. | LMRI | $901M | - | 1.54 | -8.0% | 19.62 |
| LB Pharmaceuticals Inc | LBRX | $877M | - | 2.57 | -8.4% | -20.06 |
| Bright Minds Biosciences Inc. | DRUG | $872M | - | 10.63 | -14.9% | - |
| Talkspace, Inc. | TALK | $869M |
| 129.75 |
| 7.39 |
| 6.7% |
| 128.51 |
| SELLAS Life Sciences Group, Inc. | SLS | $862M | - | 10.09 | -37.9% | - |
| Janux Therapeutics, Inc. | JANX | $860M | - | 0.89 | -11.9% | 0.55 |
| EVMN | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| Theravance Biopharma, Inc. | TBPH | $859M | 8.09 | 2.87 | 35.7% | -296.42 |
| Peer Median | - | 68.92 | 3.26 | -10.1% | -4.19 | |